Global Insulin Glargine and Lispro Market Growth 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Insulin Glargine and Lispro will have significant change from previous year. By the most conservative estimates of global Insulin Glargine and Lispro market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Insulin Glargine and Lispro market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin Glargine and Lispro market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Insulin Glargine and Lispro, covering the supply chain analysis, impact assessment to the Insulin Glargine and Lispro market size growth rate in several scenarios, and the measures to be undertaken by Insulin Glargine and Lispro companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Branded Drug
Biosimilar Drug
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Type I Dibetes
Type II Dibetes
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Sanofi S.A
Wockhardt Ltd.
Eli Lilly and Company
Cipla Limited
Gan & Lee Pharmaceutical Ltd.
Biocon Limited
Novo Nordisk A/S
Julphar Diabetes LLC
SAJA Pharmaceuticals
Merck & Co.
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Insulin Glargine and Lispro consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Insulin Glargine and Lispro market by identifying its various subsegments.
Focuses on the key global Insulin Glargine and Lispro manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Insulin Glargine and Lispro with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Insulin Glargine and Lispro submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Insulin Glargine and Lispro?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Insulin Glargine and Lispro Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Insulin Glargine and Lispro Consumption 2015-2025
2.1.2 Insulin Glargine and Lispro Consumption CAGR by Region
2.2 Insulin Glargine and Lispro Segment by Type
2.2.1 Branded Drug
2.2.2 Biosimilar Drug
2.3 Insulin Glargine and Lispro Consumption by Type
2.3.1 Global Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
2.3.2 Global Insulin Glargine and Lispro Revenue and Market Share by Type (2015-2020)
2.3.3 Global Insulin Glargine and Lispro Sale Price by Type (2015-2020)
2.4 Insulin Glargine and Lispro Segment by Application
2.4.1 Type I Dibetes
2.4.2 Type II Dibetes
2.5 Insulin Glargine and Lispro Consumption by Application
2.5.1 Global Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
2.5.2 Global Insulin Glargine and Lispro Value and Market Share by Type (2015-2020)
2.5.3 Global Insulin Glargine and Lispro Sale Price by Type (2015-2020)
3 Global Insulin Glargine and Lispro by Company
3.1 Global Insulin Glargine and Lispro Sales Market Share by Company
3.1.1 Global Insulin Glargine and Lispro Sales by Company (2018-2020)
3.1.2 Global Insulin Glargine and Lispro Sales Market Share by Company (2018-2020)
3.2 Global Insulin Glargine and Lispro Revenue Market Share by Company
3.2.1 Global Insulin Glargine and Lispro Revenue by Company (2018-2020)
3.2.2 Global Insulin Glargine and Lispro Revenue Market Share by Company (2018-2020)
3.3 Global Insulin Glargine and Lispro Sale Price by Company
3.4 Global Insulin Glargine and Lispro Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Insulin Glargine and Lispro Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Insulin Glargine and Lispro Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Insulin Glargine and Lispro by Regions
4.1 Insulin Glargine and Lispro by Regions
4.2 Americas Insulin Glargine and Lispro Consumption Growth
4.3 APAC Insulin Glargine and Lispro Consumption Growth
4.4 Europe Insulin Glargine and Lispro Consumption Growth
4.5 Middle East & Africa Insulin Glargine and Lispro Consumption Growth
5 Americas
5.1 Americas Insulin Glargine and Lispro Consumption by Countries
5.1.1 Americas Insulin Glargine and Lispro Consumption by Countries (2015-2020)
5.1.2 Americas Insulin Glargine and Lispro Value by Countries (2015-2020)
5.2 Americas Insulin Glargine and Lispro Consumption by Type
5.3 Americas Insulin Glargine and Lispro Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Insulin Glargine and Lispro Consumption by Regions
6.1.1 APAC Insulin Glargine and Lispro Consumption by Regions (2015-2020)
6.1.2 APAC Insulin Glargine and Lispro Value by Regions (2015-2020)
6.2 APAC Insulin Glargine and Lispro Consumption by Type
6.3 APAC Insulin Glargine and Lispro Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Insulin Glargine and Lispro by Countries
7.1.1 Europe Insulin Glargine and Lispro Consumption by Countries (2015-2020)
7.1.2 Europe Insulin Glargine and Lispro Value by Countries (2015-2020)
7.2 Europe Insulin Glargine and Lispro Consumption by Type
7.3 Europe Insulin Glargine and Lispro Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Insulin Glargine and Lispro by Countries
8.1.1 Middle East & Africa Insulin Glargine and Lispro Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Insulin Glargine and Lispro Value by Countries (2015-2020)
8.2 Middle East & Africa Insulin Glargine and Lispro Consumption by Type
8.3 Middle East & Africa Insulin Glargine and Lispro Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Insulin Glargine and Lispro Distributors
10.3 Insulin Glargine and Lispro Customer
11 Global Insulin Glargine and Lispro Market Forecast
11.1 Global Insulin Glargine and Lispro Consumption Forecast (2021-2025)
11.2 Global Insulin Glargine and Lispro Forecast by Regions
11.2.1 Global Insulin Glargine and Lispro Forecast by Regions (2021-2025)
11.2.2 Global Insulin Glargine and Lispro Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Insulin Glargine and Lispro Forecast by Type
11.8 Global Insulin Glargine and Lispro Forecast by Application
12 Key Players Analysis
12.1 Sanofi S.A
12.1.1 Company Information
12.1.2 Insulin Glargine and Lispro Product Offered
12.1.3 Sanofi S.A Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Sanofi S.A Latest Developments
12.2 Wockhardt Ltd.
12.2.1 Company Information
12.2.2 Insulin Glargine and Lispro Product Offered
12.2.3 Wockhardt Ltd. Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Wockhardt Ltd. Latest Developments
12.3 Eli Lilly and Company
12.3.1 Company Information
12.3.2 Insulin Glargine and Lispro Product Offered
12.3.3 Eli Lilly and Company Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Eli Lilly and Company Latest Developments
12.4 Cipla Limited
12.4.1 Company Information
12.4.2 Insulin Glargine and Lispro Product Offered
12.4.3 Cipla Limited Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Cipla Limited Latest Developments
12.5 Gan & Lee Pharmaceutical Ltd.
12.5.1 Company Information
12.5.2 Insulin Glargine and Lispro Product Offered
12.5.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Gan & Lee Pharmaceutical Ltd. Latest Developments
12.6 Biocon Limited
12.6.1 Company Information
12.6.2 Insulin Glargine and Lispro Product Offered
12.6.3 Biocon Limited Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Biocon Limited Latest Developments
12.7 Novo Nordisk A/S
12.7.1 Company Information
12.7.2 Insulin Glargine and Lispro Product Offered
12.7.3 Novo Nordisk A/S Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Novo Nordisk A/S Latest Developments
12.8 Julphar Diabetes LLC
12.8.1 Company Information
12.8.2 Insulin Glargine and Lispro Product Offered
12.8.3 Julphar Diabetes LLC Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Julphar Diabetes LLC Latest Developments
12.9 SAJA Pharmaceuticals
12.9.1 Company Information
12.9.2 Insulin Glargine and Lispro Product Offered
12.9.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 SAJA Pharmaceuticals Latest Developments
12.10 Merck & Co.
12.10.1 Company Information
12.10.2 Insulin Glargine and Lispro Product Offered
12.10.3 Merck & Co. Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Merck & Co. Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Insulin Glargine and Lispro Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Insulin Glargine and Lispro Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Insulin Glargine and Lispro Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Branded Drug
Table 7. Major Players of Biosimilar Drug
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
Table 10. Global Insulin Glargine and Lispro Revenue by Type (2015-2020) ($ million)
Table 11. Global Insulin Glargine and Lispro Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global Insulin Glargine and Lispro Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global Insulin Glargine and Lispro Consumption Market Share by Application (2015-2020)
Table 15. Global Insulin Glargine and Lispro Value by Application (2015-2020)
Table 16. Global Insulin Glargine and Lispro Value Market Share by Application (2015-2020)
Table 17. Global Insulin Glargine and Lispro Sale Price by Application (2015-2020)
Table 18. Global Insulin Glargine and Lispro Sales by Company (2017-2019) (Liter)
Table 19. Global Insulin Glargine and Lispro Sales Market Share by Company (2017-2019)
Table 20. Global Insulin Glargine and Lispro Revenue by Company (2017-2019) ($ Millions)
Table 21. Global Insulin Glargine and Lispro Revenue Market Share by Company (2017-2019)
Table 22. Global Insulin Glargine and Lispro Sale Price by Company (2017-2019)
Table 23. Global Insulin Glargine and Lispro Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players Insulin Glargine and Lispro Products Offered
Table 25. Insulin Glargine and Lispro Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global Insulin Glargine and Lispro Consumption by Regions 2015-2020 (Liter)
Table 27. Global Insulin Glargine and Lispro Consumption Market Share by Regions 2015-2020
Table 28. Global Insulin Glargine and Lispro Value by Regions 2015-2020 ($ Millions)
Table 29. Global Insulin Glargine and Lispro Value Market Share by Regions 2015-2020
Table 30. Americas Insulin Glargine and Lispro Consumption by Countries (2015-2020) (Liter)
Table 31. Americas Insulin Glargine and Lispro Consumption Market Share by Countries (2015-2020)
Table 32. Americas Insulin Glargine and Lispro Value by Countries (2015-2020) ($ Millions)
Table 33. Americas Insulin Glargine and Lispro Value Market Share by Countries (2015-2020)
Table 34. Americas Insulin Glargine and Lispro Consumption by Type (2015-2020) (Liter)
Table 35. Americas Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
Table 36. Americas Insulin Glargine and Lispro Consumption by Application (2015-2020) (Liter)
Table 37. Americas Insulin Glargine and Lispro Consumption Market Share by Application (2015-2020)
Table 38. APAC Insulin Glargine and Lispro Consumption by Countries (2015-2020) (Liter)
Table 39. APAC Insulin Glargine and Lispro Consumption Market Share by Countries (2015-2020)
Table 40. APAC Insulin Glargine and Lispro Value by Regions (2015-2020) ($ Millions)
Table 41. APAC Insulin Glargine and Lispro Value Market Share by Regions (2015-2020)
Table 42. APAC Insulin Glargine and Lispro Consumption by Type (2015-2020) (Liter)
Table 43. APAC Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
Table 44. APAC Insulin Glargine and Lispro Consumption by Application (2015-2020) (Liter)
Table 45. APAC Insulin Glargine and Lispro Consumption Market Share by Application (2015-2020)
Table 46. Europe Insulin Glargine and Lispro Consumption by Countries (2015-2020) (Liter)
Table 47. Europe Insulin Glargine and Lispro Consumption Market Share by Countries (2015-2020)
Table 48. Europe Insulin Glargine and Lispro Value by Countries (2015-2020) ($ Millions)
Table 49. Europe Insulin Glargine and Lispro Value Market Share by Countries (2015-2020)
Table 50. Europe Insulin Glargine and Lispro Consumption by Type (2015-2020) (Liter)
Table 51. Europe Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
Table 52. Europe Insulin Glargine and Lispro Consumption by Application (2015-2020) (Liter)
Table 53. Europe Insulin Glargine and Lispro Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa Insulin Glargine and Lispro Consumption by Countries (2015-2020) (Liter)
Table 55. Middle East & Africa Insulin Glargine and Lispro Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Insulin Glargine and Lispro Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa Insulin Glargine and Lispro Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Insulin Glargine and Lispro Consumption by Type (2015-2020) (Liter)
Table 59. Middle East & Africa Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa Insulin Glargine and Lispro Consumption by Application (2015-2020) (Liter)
Table 61. Middle East & Africa Insulin Glargine and Lispro Consumption Market Share by Application (2015-2020)
Table 62. Insulin Glargine and Lispro Distributors List
Table 63. Insulin Glargine and Lispro Customer List
Table 64. Global Insulin Glargine and Lispro Consumption Forecast by Countries (2021-2025) (Liter)
Table 65. Global Insulin Glargine and Lispro Consumption Market Forecast by Regions
Table 66. Global Insulin Glargine and Lispro Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global Insulin Glargine and Lispro Value Market Share Forecast by Regions
Table 68. Global Insulin Glargine and Lispro Consumption Forecast by Type (2021-2025) (Liter)
Table 69. Global Insulin Glargine and Lispro Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global Insulin Glargine and Lispro Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global Insulin Glargine and Lispro Value Market Share Forecast by Type (2021-2025)
Table 72. Global Insulin Glargine and Lispro Consumption Forecast by Application (2021-2025) (Liter)
Table 73. Global Insulin Glargine and Lispro Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global Insulin Glargine and Lispro Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global Insulin Glargine and Lispro Value Market Share Forecast by Application (2021-2025)
Table 76. Sanofi S.A Product Offered
Table 77. Sanofi S.A Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 78. Sanofi S.A Main Business
Table 79. Sanofi S.A Latest Developments
Table 80. Sanofi S.A Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 81. Wockhardt Ltd. Product Offered
Table 82. Wockhardt Ltd. Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 83. Wockhardt Ltd. Main Business
Table 84. Wockhardt Ltd. Latest Developments
Table 85. Wockhardt Ltd. Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 86. Eli Lilly and Company Product Offered
Table 87. Eli Lilly and Company Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 88. Eli Lilly and Company Main Business
Table 89. Eli Lilly and Company Latest Developments
Table 90. Eli Lilly and Company Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 91. Cipla Limited Product Offered
Table 92. Cipla Limited Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 93. Cipla Limited Main Business
Table 94. Cipla Limited Latest Developments
Table 95. Cipla Limited Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 96. Gan & Lee Pharmaceutical Ltd. Product Offered
Table 97. Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 98. Gan & Lee Pharmaceutical Ltd. Main Business
Table 99. Gan & Lee Pharmaceutical Ltd. Latest Developments
Table 100. Gan & Lee Pharmaceutical Ltd. Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 101. Biocon Limited Product Offered
Table 102. Biocon Limited Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 103. Biocon Limited Main Business
Table 104. Biocon Limited Latest Developments
Table 105. Biocon Limited Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 106. Novo Nordisk A/S Product Offered
Table 107. Novo Nordisk A/S Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 108. Novo Nordisk A/S Main Business
Table 109. Novo Nordisk A/S Latest Developments
Table 110. Novo Nordisk A/S Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 111. Julphar Diabetes LLC Product Offered
Table 112. Julphar Diabetes LLC Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 113. Julphar Diabetes LLC Main Business
Table 114. Julphar Diabetes LLC Latest Developments
Table 115. Julphar Diabetes LLC Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 116. SAJA Pharmaceuticals Product Offered
Table 117. SAJA Pharmaceuticals Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 118. SAJA Pharmaceuticals Main Business
Table 119. SAJA Pharmaceuticals Latest Developments
Table 120. SAJA Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
Table 121. Merck & Co. Product Offered
Table 122. Merck & Co. Insulin Glargine and Lispro Sales (Liter), Revenue ($ Million), Price (USD/mL) and Gross Margin (2018-2020E)
Table 123. Merck & Co. Main Business
Table 124. Merck & Co. Latest Developments
Table 125. Merck & Co. Basic Information, Company Total Revenue (in $ million), Insulin Glargine and Lispro Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Insulin Glargine and Lispro
Figure 2. Insulin Glargine and Lispro Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Insulin Glargine and Lispro Consumption Growth Rate 2015-2025 (Liter)
Figure 5. Global Insulin Glargine and Lispro Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Branded Drug
Figure 7. Product Picture of Biosimilar Drug
Figure 8. Global Insulin Glargine and Lispro Consumption Market Share by Type (2015-2020)
Figure 9. Global Insulin Glargine and Lispro Value Market Share by Type (2015-2020)
Figure 10. Insulin Glargine and Lispro Consumed in Type I Dibetes
Figure 11. Global Insulin Glargine and Lispro Market: Type I Dibetes (2015-2020) (Liter)
Figure 12. Global Insulin Glargine and Lispro Market: Type I Dibetes (2015-2020) ($ Millions)
Figure 13. Insulin Glargine and Lispro Consumed in Type II Dibetes
Figure 14. Global Insulin Glargine and Lispro Market: Type II Dibetes (2015-2020) (Liter)
Figure 15. Global Insulin Glargine and Lispro Market: Type II Dibetes (2015-2020) ($ Millions)
Figure 16. Global Insulin Glargine and Lispro Consumption Market Share by Application (2015-2020)
Figure 17. Global Insulin Glargine and Lispro Value Market Share by Application (2015-2020)
Figure 18. Global Insulin Glargine and Lispro Sales Market Share by Company in 2017
Figure 19. Global Insulin Glargine and Lispro Sales Market Share by Company in 2019
Figure 20. Global Insulin Glargine and Lispro Revenue Market Share by Company in 2017
Figure 21. Global Insulin Glargine and Lispro Revenue Market Share by Company in 2019
Figure 22. Global Insulin Glargine and Lispro Sale Price by Company in 2019
Figure 23. Global Insulin Glargine and Lispro Consumption Market Share by Regions 2015-2020
Figure 24. Global Insulin Glargine and Lispro Value Market Share by Regions 2015-2020
Figure 25. Americas Insulin Glargine and Lispro Consumption 2015-2020 (Liter)
Figure 26. Americas Insulin Glargine and Lispro Value 2015-2020 ($ Millions)
Figure 27. APAC Insulin Glargine and Lispro Consumption 2015-2020 (Liter)
Figure 28. APAC Insulin Glargine and Lispro Value 2015-2020 ($ Millions)
Figure 29. Europe Insulin Glargine and Lispro Consumption 2015-2020 (Liter)
Figure 30. Europe Insulin Glargine and Lispro Value 2015-2020 ($ Millions)
Figure 31. Middle East & Africa Insulin Glargine and Lispro Consumption 2015-2020 (Liter)
Figure 32. Middle East & Africa Insulin Glargine and Lispro Value 2015-2020 ($ Millions)
Figure 33. Americas Insulin Glargine and Lispro Consumption Market Share by Countries in 2019
Figure 34. Americas Insulin Glargine and Lispro Value Market Share by Countries in 2019
Figure 35. Americas Insulin Glargine and Lispro Consumption Market Share by Type in 2019
Figure 36. Americas Insulin Glargine and Lispro Consumption Market Share by Application in 2019
Figure 37. United States Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 38. United States Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 39. Canada Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 40. Canada Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 41. Mexico Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 42. Mexico Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 43. APAC Insulin Glargine and Lispro Consumption Market Share by Countries in 2019
Figure 44. APAC Insulin Glargine and Lispro Value Market Share by Regions in 2019
Figure 45. APAC Insulin Glargine and Lispro Consumption Market Share by Type in 2019
Figure 46. APAC Insulin Glargine and Lispro Consumption Market Share by Application in 2019
Figure 47. China Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 48. China Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 49. Japan Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 50. Japan Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 51. Korea Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 52. Korea Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 53. Southeast Asia Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 54. Southeast Asia Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 55. India Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 56. India Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 57. Australia Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 58. Australia Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 59. Europe Insulin Glargine and Lispro Consumption Market Share by Countries in 2019
Figure 60. Europe Insulin Glargine and Lispro Value Market Share by Countries in 2019
Figure 61. Europe Insulin Glargine and Lispro Consumption Market Share by Type in 2019
Figure 62. Europe Insulin Glargine and Lispro Consumption Market Share by Application in 2019
Figure 63. Germany Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 64. Germany Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 65. France Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 66. France Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 67. UK Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 68. UK Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 69. Italy Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 70. Italy Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 71. Russia Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 72. Russia Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 73. Middle East & Africa Insulin Glargine and Lispro Consumption Market Share by Countries in 2019
Figure 74. Middle East & Africa Insulin Glargine and Lispro Value Market Share by Countries in 2019
Figure 75. Middle East & Africa Insulin Glargine and Lispro Consumption Market Share by Type in 2019
Figure 76. Middle East & Africa Insulin Glargine and Lispro Consumption Market Share by Application in 2019
Figure 77. Egypt Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 78. Egypt Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 79. South Africa Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 80. South Africa Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 81. Israel Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 82. Israel Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 83. Turkey Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 84. Turkey Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 85. GCC Countries Insulin Glargine and Lispro Consumption Growth 2015-2020 (Liter)
Figure 86. GCC Countries Insulin Glargine and Lispro Value Growth 2015-2020 ($ Millions)
Figure 87. Global Insulin Glargine and Lispro Consumption Growth Rate Forecast (2021-2025) (Liter)
Figure 88. Global Insulin Glargine and Lispro Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 89. Americas Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 90. Americas Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 91. APAC Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 92. APAC Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 93. Europe Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 94. Europe Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 95. Middle East & Africa Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 96. Middle East & Africa Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 97. United States Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 98. United States Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 99. Canada Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 100. Canada Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 101. Mexico Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 102. Mexico Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 103. Brazil Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 104. Brazil Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 105. China Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 106. China Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 107. Japan Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 108. Japan Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 109. Korea Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 110. Korea Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 111. Southeast Asia Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 112. Southeast Asia Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 113. India Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 114. India Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 115. Australia Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 116. Australia Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 117. Germany Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 118. Germany Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 119. France Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 120. France Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 121. UK Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 122. UK Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 123. Italy Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 124. Italy Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 125. Russia Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 126. Russia Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 127. Spain Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 128. Spain Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 129. Egypt Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 130. Egypt Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 131. South Africa Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 132. South Africa Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 133. Israel Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 134. Israel Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 135. Turkey Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 136. Turkey Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 137. GCC Countries Insulin Glargine and Lispro Consumption 2021-2025 (Liter)
Figure 138. GCC Countries Insulin Glargine and Lispro Value 2021-2025 ($ Millions)
Figure 139. Sanofi S.A Insulin Glargine and Lispro Market Share (2018-2020)
Figure 140. Wockhardt Ltd. Insulin Glargine and Lispro Market Share (2018-2020)
Figure 141. Eli Lilly and Company Insulin Glargine and Lispro Market Share (2018-2020)
Figure 142. Cipla Limited Insulin Glargine and Lispro Market Share (2018-2020)
Figure 143. Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Market Share (2018-2020)
Figure 144. Biocon Limited Insulin Glargine and Lispro Market Share (2018-2020)
Figure 145. Novo Nordisk A/S Insulin Glargine and Lispro Market Share (2018-2020)
Figure 146. Julphar Diabetes LLC Insulin Glargine and Lispro Market Share (2018-2020)
Figure 147. SAJA Pharmaceuticals Insulin Glargine and Lispro Market Share (2018-2020)
Figure 148. Merck & Co. Insulin Glargine and Lispro Market Share (2018-2020)
